Launched in 2009, the Ophthalmology Innovation Summit serves to showcase ... an exchange of information and connections to drive innovation in the retina, anterior segment, and optometry. About ...

Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...

Within the treated group, eyes with plus disease had consistently lower C/D values than those without plus disease, a finding the study authors say may result from obscuring of the optic cup by ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of ...

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

Clearside’s innovative SCS Microinjector is being used in commercial ophthalmic products and promising clinical development programs by Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, ...

Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile ...

LAS VEGAS — In this video, Baruch D. Kuppermann, MD, PhD, of University of California, Irvine, discusses presentations on neovascular age-related macular degeneration at Clinical Trials at ...